Mario Galindo

Mario Galindo

Auto-generated profile, based on publicly available information

Mario Galindo

Millennium Institute on Immunology and Immunotherapy, University of Chile, Santiago, Chile

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003
Verified
Journal Article
Closed access
JPJitesh Pratap
Jitesh Pratap
MGMario Galindo
Mario Galindo
SZS Kaleem Zaidi
S Kaleem Zaidi
DVDiana Vradii
Diana Vradii
BBBheem M Bhat
Bheem M Bhat
Andre J. van WijnenAndre J. van Wijnen
Andre J. van Wijnen

4 September 2012 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
CLClaudia M.J. Lucero
Claudia M.J. Lucero
OVOscar A. Vega
Oscar A. Vega
MOMariana M. Osorio
Mariana M. Osorio
JTJulio C. Tapia
Julio C. Tapia
MAMarcelo Antonelli
Marcelo Antonelli
MGMario A. Galindo
Mario A. Galindo

1 March 2022 in Microbial Drug Resistance
Verified
Journal Article
Closed access
Luis Esaú López-JácomeLuis Esaú López-Jácome
Luis Esaú López-Jácome
DFDiana Fernández-Rodríguez
Diana Fernández-Rodríguez
RFRafael Franco-Cendejas
Rafael Franco-Cendejas
ACAdrián Camacho-Ortiz
Adrián Camacho-Ortiz
RMRayo Morfin-Otero
Rayo Morfin-Otero
Elvira Garza-GonzálezElvira Garza-González
Elvira Garza-González
Aim: This study aims to assess the changes in antimicrobial resistance among some critical and high-priority microorganisms collected previously and during the coronavirus disease 2019 (COVID-19) pandemic in Mexico. Methods: We collected antimicrobial susceptibility data for critical and high-priority microorganisms from blood, urine, respiratory samples, and from all specimens, in which the pathogen may be considered a causative agent. Data were stratified and compared for two periods: 2019 versus 2020 and second semester 2019 (prepandemic) versus the second semester 2020 (pandemic). Results: In the analysis of second semester 2019 versus the second semester 2020, in blood samples, increased resistance to oxacillin (15.2% vs. 36.9%), erythromycin (25.7% vs. 42.8%), and clindamycin (24.8% vs. 43.3%) ( p ≤ 0.01) was detected for Staphylococcus aureus , to imipenem (13% vs. 23.4%) and meropenem (11.2% vs. 21.4) ( p ≤ 0.01), for Klebsiella pneumoniae . In all specimens, increased ampicillin and tetracycline resistance was detected for Enterococcus faecium ( p ≤ 0.01). In cefepime, meropenem, levofloxacin, and gentamicin ( p ≤ 0.01), resistance was detected for Escherichia coli ; and in piperacillin-tazobactam, cefepime, imipenem, meropenem, ciprofloxacin, levofloxacin, and gentamicin ( p ≤ 0.01), resistance was detected for Pseudomonas aeruginosa . Conclusion: Antimicrobial resistance increased in Mexico during the COVID-19 pandemic. The increase in oxacillin resistance for S. aureus and carbapenem resistance for K. pneumoniae recovered from blood specimens deserves special attention. In addition, an increase in erythromycin resistance in S. aureus was detected, which may be associated with high azithromycin use. In general, for Acinetobacter baumannii and P. aeruginosa , increasing resistance rates were detected.

30 June 2016 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
SJSofía Jerez
Sofía Jerez
HAHéctor Araya
Héctor Araya
RTRoman Thaler
Roman Thaler
MCM. Cristine Charlesworth
M. Cristine Charlesworth
RLRemigio López-Solís
Remigio López-Solís
MGMario Galindo
Mario Galindo

25 September 2009 in Journal of Cellular Physiology
Verified
Journal Article
Open access
PDF file
IMInga A. San Martin
Inga A. San Martin
NVNelson Varela
Nelson Varela
MGMarcia Gaete
Marcia Gaete
KVKarina Villegas
Karina Villegas
MOMariana Osorio
Mariana Osorio
MGMario Galindo
Mario Galindo
Bone formation and osteoblast differentiation require the functional expression of the Runx2/Cbfβ heterodimeric transcription factor complex. Runx2 is also a suppressor of proliferation in osteoblasts by attenuating cell cycle progression in G1. Runx2 levels are modulated during the cell cycle, which are maximal in G1 and minimal beyond the G1/S phase transition (S, G2, and M phases). It is not known whether Cbfβ gene expression is cell cycle controlled in preosteoblasts nor how Runx2 or Cbfβ are regulated during the cell cycle in bone cancer cells. We investigated Runx2 and Cbfβ gene expression during cell cycle progression in MC3T3‐E1 osteoblasts, as well as ROS17/2.8 and SaOS‐2 osteosarcoma cells. Runx2 protein levels are reduced as expected in MC3T3‐E1 cells arrested in late G1 (by mimosine) or M phase (by nocodazole), but not in cell cycle arrested osteosarcoma cells. Cbfβ protein levels are cell cycle independent in both osteoblasts and osteosarcoma cells. In synchronized MC3T3‐E1 osteoblasts progressing from late G1 or mitosis, Runx2 levels but not Cbfβ levels are cell cycle regulated. However, both factors are constitutively elevated throughout the cell cycle in osteosarcoma cells. Proteasome inhibition by MG132 stabilizes Runx2 protein levels in late G1 and S in MC3T3‐E1 cells, but not in ROS17/2.8 and SaOS‐2 osteosarcoma cells. Thus, proteasomal degradation of Runx2 is deregulated in osteosarcoma cells. We propose that cell cycle control of Runx2 gene expression is impaired in osteosarcomas and that this deregulation may contribute to the pathogenesis of osteosarcoma. J. Cell. Physiol. 221: 560–571, 2009.

28 March 2017 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
OVOscar A. Vega
Oscar A. Vega
CLClaudia M.J. Lucero
Claudia M.J. Lucero
HAHector F. Araya
Hector F. Araya
SJSofia Jerez
Sofia Jerez
JTJulio C. Tapia
Julio C. Tapia
MGMario A. Galindo
Mario A. Galindo